Human bioavailability study of benznidazole for treatment of Chagas disease, a neglected tropical disease.

Trial Profile

Human bioavailability study of benznidazole for treatment of Chagas disease, a neglected tropical disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Benznidazole (Primary)
  • Indications Chagas disease
  • Focus Pharmacokinetics
  • Sponsors Humanigen
  • Most Recent Events

    • 14 Aug 2017 New trial record
    • 09 Aug 2017 According to Humanigen media release, company received clearance from the FDA in June 2017 for its Investigational New Drug (IND) application for benznidazole.
    • 09 Aug 2017 According to Humanigen media release, analysis of the study has begun and anicipates its preliminary results by Oct 2017. Also, the final study report will expect in fourth quater of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top